We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letter |

Fluorouracil and Other Predictors of Morpheaform Basal Cell Carcinoma Among High-Risk Patients: The Veterans Affairs Topical Tretinoin Chemoprevention Trial

Michael Y. Xiong, BA1,2; Kaveri Korgavkar, BS1,2; John J. DiGiovanna, MD3; Martin A. Weinstock, MD, PhD1,2,4,5; for the Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) Trial Group
[+] Author Affiliations
1Dermatoepidemiology Unit, VA Medical Center, Providence, Rhode Island
2Department of Dermatology, Warren Alpert Medical School of Brown University, Providence, Rhode Island
3DNA Repair Section, Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
4Department of Dermatology, Rhode Island Hospital, Providence
5Department of Epidemiology, Brown University, Providence, Rhode Island
JAMA Dermatol. 2014;150(3):332-334. doi:10.1001/jamadermatol.2013.5619.
Text Size: A A A
Published online


Although basal cell carcinoma (BCC) overall is less aggressive than other forms of skin cancer, the morpheaform subtype is particularly concerning because of its benign appearance and aggressive subclinical spread. We sought to evaluate risk factors for its development on the face or ears in a high-risk population of veterans with at least 2 prior keratinocyte carcinomas in the Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) Trial.

Article InformationCorresponding Author: Martin A. Weinstock, MD, PhD, Dermatoepidemiology Unit, VA Medical Center, Mail Code 111D, 830 Chalkstone Ave, Providence, RI 02908 (maw@brown.edu).

Accepted for Publication: May 23, 2013.

Published Online: November 20, 2013. doi:10.1001/jamadermatol.2013.5619.

Author Contributions: Dr Weinstock had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Xiong, DiGiovanna, Weinstock.

Acquisition of data: Xiong, Weinstock.

Analysis of data: All authors.

Drafting of the manuscript: Xiong, Korgavkar, Weinstock.

Critical revision of manuscript for important intellectual content: All authors.

Statistical analysis: Xiong, Weinstock.

Obtained funding: Weinstock.

Administrative, technical, or material support: DiGiovanna, Weinstock.

Study supervision: Weinstock.

Conflict of Interest Disclosures: None reported.

Funding/Support: This study was supported in part by the VA Cooperative Studies Program (CSP) (grant CSP 402), Office of Research and Development, Department of Veterans Affairs (VA).

Role of the Sponsor: Because this was a VA CSP trial, the VA necessarily played a role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; and the preparation, review, and approval of the manuscript,

Group Information: Key personnel for the VATTC Trial Group Study Chair’s Office: Martin A. Weinstock, MD, PhD (chair), and Kimberly Marcolivio, MEd (Providence VA Medical Center [VAMC], Rhode Island). Executive Committee: Martin A. Weinstock (Providence), Stephen Bingham, PhD (Perry Point, Maryland), John J. DiGiovanna, MD (Providence), Russell Hall, MD (Durham, North Carolina), Mark Naylor, MD (Oklahoma City), J. Richard Taylor, MD (Miami, Florida), Julia Vertrees, PharmD (Albuquerque, New Mexico), and Clifton White, MD (Portland, Oregon). Clinical Centers: Durham VAMC, Durham: Russell Hall and Deborah Hannah; Hines VA Hospital, Chicago, Illinois: David Eilers, Tehming Liang, Nadia Sakla, and Ann Kreuger; Long Beach VAMC, Long Beach, California: Gary Cole, Edward Jeffes, and Terri Labrador; Miami VAMC, Miami, Florida: J. Richard Taylor, Robert Kirsner, Jonette E. Kerri, Anna G. Falabella, and Margarita Givens; Oklahoma City VAMC, Oklahoma City: Mark Naylor, Mary Beth Benson, and Lisa Perry; and Phoenix VAMC, Phoenix, Arizona: James Kalivas, Catherine Yanni, Selma Targovnik, Janet Austin, and Susan Collier. Cooperative Studies Program Coordinating Center, Perry Point: Joseph F. Collins, Stephen Bingham, Beverly Calvert, Philip Connor, Colleen Crigler, Dawn Davis, Pat Grubb, Judy Kelly, Gail Kirk, Karen Lawson, Linda Linzy, Lorrine Palmer, and Maxine Rhoads. Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque: Mike Sather, Erica Copeland, Carol Fye, William Gagne, Patricia Grimes de Naranjo, Chad Messick, and Julia Vertrees. Dermatopathologists: Michael Piepkorn (Bellevue, Washington) and Clifton White (Portland). Data and Safety Monitoring Board: Robert Lew (Boston, Massachusetts), Irwin Braverman (New Haven, Connecticut), Bernard Cole (Lebanon, New Hampshire), Richard Kalish (Stony Brook, New York), David McLean (Vancouver, British Columbia, Canada), and Bruce Harris Thiers (Charleston, South Carolina).

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles